• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.在德国进行的一项观察性研究结果：用于启动抗逆转录病毒治疗的基于利托那韦增强型蛋白酶抑制剂和非核苷类逆转录酶抑制剂方案之间的选择
J Pharm Policy Pract. 2016 Dec 30;9:39. doi: 10.1186/s40545-016-0092-4. eCollection 2016.
2
Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data.德国初治HIV患者的治疗策略：来自理赔数据的证据
Springerplus. 2015 Jul 1;4:306. doi: 10.1186/s40064-015-1099-z. eCollection 2015.
3
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.三种高效抗逆转录病毒治疗策略的比较：在核苷类逆转录酶抑制剂存在的情况下，分别使用非核苷类逆转录酶抑制剂、蛋白酶抑制剂或两者联合作为初始治疗（CPCRA 058 FIRST研究）：一项长期随机试验。
Lancet. 2006 Dec 16;368(9553):2125-35. doi: 10.1016/S0140-6736(06)69861-9.
4
Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.启动基于非核苷类逆转录酶抑制剂与利托那韦增强型蛋白酶抑制剂的抗逆转录病毒疗法的长期疗效：对资源有限环境中一线治疗选择的影响
J Int AIDS Soc. 2016 Aug 5;19(1):20978. doi: 10.7448/IAS.19.1.20978. eCollection 2016.
5
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.阿巴卡韦/拉米夫定联合达芦那韦/利托那韦与其他蛋白酶抑制剂对临床实践中接受过治疗的HIV感染患者的病毒学疗效
Clin Drug Investig. 2017 Jan;37(1):51-60. doi: 10.1007/s40261-016-0456-1.
6
Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.2000年1月1日之后开始接受抗逆转录病毒治疗的初治患者中，含单一和强化蛋白酶抑制剂的抗逆转录病毒治疗方案与含非核苷类逆转录酶抑制剂的抗逆转录病毒治疗方案的比较。
HIV Clin Trials. 2006 Nov-Dec;7(6):271-84. doi: 10.1310/hct0706-271.
7
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.在瑞士HIV队列研究中，初治抗逆转录病毒治疗患者开始基于蛋白酶抑制剂（PI）和非核苷类逆转录酶抑制剂（NNRTI）治疗时的血脂谱。
Antivir Ther. 2005;10(5):585-91.
8
Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.在资源有限的环境中，基于增强型蛋白酶抑制剂的治疗方案对接受基于非核苷类逆转录酶抑制剂的抗逆转录病毒治疗后出现病毒学失败的1型人类免疫缺陷病毒感染患者的疗效。
AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48. doi: 10.1089/aid.2009.0125.
9
Sociodemographic and clinical factors associated with the preference between NNRTIs and PIs for the initial treatment of HIV infection: Perfil-es study.与在HIV感染初始治疗中选择非核苷类逆转录酶抑制剂（NNRTIs）和蛋白酶抑制剂（PIs）的偏好相关的社会人口统计学和临床因素：Perfil-es研究
AIDS Care. 2016 Oct;28(10):1321-6. doi: 10.1080/09540121.2016.1173640. Epub 2016 May 3.
10
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.初治患者开始联合抗逆转录病毒治疗时HIV-1耐药性的出现：不同治疗方案类型的比较
Arch Intern Med. 2007 Sep 10;167(16):1782-90. doi: 10.1001/archinte.167.16.1782.

引用本文的文献

1
A Case Report of Multiclass HIV Drug-Resistance After an Inappropriate Switch of ARVs with Persistent Unsuppressed Viral Load.多药耐药 HIV 病例报告：在持续未抑制病毒载量的情况下，不适当转换 ARV 导致耐药。
J Int Assoc Provid AIDS Care. 2022 Jan-Dec;21:23259582221110454. doi: 10.1177/23259582221110454.
2
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.一项在初治 HIV-1 患者中进行的达芦那韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺的 48 周随机 3 期临床试验。
AIDS. 2018 Jul 17;32(11):1431-1442. doi: 10.1097/QAD.0000000000001817.
3
Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data.德国初治HIV患者的治疗策略：来自理赔数据的证据
Springerplus. 2015 Jul 1;4:306. doi: 10.1186/s40064-015-1099-z. eCollection 2015.

本文引用的文献

1
Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines.德国当代艾滋病毒/艾滋病医疗保健成本分析：驱动因素及抗逆转录病毒治疗方案的费用分布
Medicine (Baltimore). 2016 Jun;95(26):e3961. doi: 10.1097/MD.0000000000003961.
2
Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials.非核苷类逆转录酶抑制剂与利托那韦增强型蛋白酶抑制剂为基础的方案用于初始治疗HIV感染的随机试验的系统评价和荟萃分析
Clin Infect Dis. 2016 Jul 15;63(2):268-80. doi: 10.1093/cid/ciw236. Epub 2016 Apr 18.
3
[Antiretroviral therapy for HIV/AIDS in claims data from statutory health insurance funds in Germany].[德国法定健康保险基金理赔数据中的艾滋病病毒/艾滋病抗逆转录病毒治疗]
Z Evid Fortbild Qual Gesundhwes. 2015;109(8):594-604. doi: 10.1016/j.zefq.2014.09.002. Epub 2014 Nov 29.
4
Treatment strategies for treatment naïve HIV patients in Germany: evidence from claims data.德国初治HIV患者的治疗策略：来自理赔数据的证据
Springerplus. 2015 Jul 1;4:306. doi: 10.1186/s40064-015-1099-z. eCollection 2015.
5
Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.三种抗逆转录病毒治疗方案类型依从性不同的患者之间HIV病毒学失败率的比较。
AIDS Patient Care STDS. 2015 Jul;29(7):384-8. doi: 10.1089/apc.2014.0165. Epub 2015 Jun 4.
6
[Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].[德国接受抗逆转录病毒治疗的艾滋病患者的疾病成本——前瞻性多中心观察性研究“CORSAR”48周中期分析结果]
Gesundheitswesen. 2015 Jun;77(6):e133-42. doi: 10.1055/s-0034-1381993. Epub 2014 Sep 23.
7
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.依法韦仑作为HIV-1感染初始治疗与自杀意念、自杀未遂或自杀死亡风险增加之间的关联：试验数据分析
Ann Intern Med. 2014 Jul 1;161(1):1-10. doi: 10.7326/M14-0293.
8
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.一项关于在欧洲 HIV 阳性人群中作为一线治疗药物使用 ATRIPLA 的临床实践调查。
Infection. 2014 Aug;42(4):757-62. doi: 10.1007/s15010-014-0630-4. Epub 2014 Jun 6.
9
Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment.评估 AIDS/HIV 治疗中医生判断与患者偏好的一致性 - 离散选择实验。
Health Econ Rev. 2013 Dec 18;3(1):30. doi: 10.1186/2191-1991-3-30.
10
Patient preferences for HIV/AIDS therapy - a discrete choice experiment.患者对 HIV/AIDS 疗法的偏好 - 离散选择实验。
Health Econ Rev. 2013 May 11;3(1):14. doi: 10.1186/2191-1991-3-14.

在德国进行的一项观察性研究结果：用于启动抗逆转录病毒治疗的基于利托那韦增强型蛋白酶抑制剂和非核苷类逆转录酶抑制剂方案之间的选择

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany.

作者信息

Mahlich Jörg, Groß Mona, Kuhlmann Alexander, Bogner Johannes, Heiken Hans, Stoll Matthias

机构信息

Janssen KK, Health Economics, Tokyo, Japan ; Heinrich-Heine University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE), Düsseldorf, Germany.

Heinrich-Heine University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE), Düsseldorf, Germany.

出版信息

J Pharm Policy Pract. 2016 Dec 30;9:39. doi: 10.1186/s40545-016-0092-4. eCollection 2016.

DOI:10.1186/s40545-016-0092-4
PMID:28050254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5203724/
Abstract

BACKGROUND

This study aims at identifying predictors of the treatment decision of German physicians with regard to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r) -based initial treatment regimen.

METHODS

The study is based on a sub analysis of a nation-wide multi-centre, non-interventional, prospective cohort study. 133 patients were identified, who received antiretroviral first-line therapy. By means of a logistic regression, factors that determine the treatment strategy for treatment-naïve patients were analysed.

RESULTS

Compared to patients receiving a NNRTI-based initial regimen, patients treated with PI/r are slightly younger, less educated, in a later stage of HIV and have more concomitant diseases. Regression analysis revealed that being in a later stage of HIV (CDC-C) is significantly associated with a PI/r-based treatment decision.

CONCLUSIONS

Our analysis is the first study in Germany investigating sociodemographic and disease-specific parameters associated with a NNRTI- or a PI/r-based initial treatment decision. The results confirm that the treatment decision for a PI/r strategy is associated with disease severity.

摘要

背景

本研究旨在确定德国医生对于基于非核苷类逆转录酶抑制剂（NNRTI）或利托那韦增强型蛋白酶抑制剂（PI/r）的初始治疗方案的治疗决策预测因素。

方法

本研究基于一项全国性多中心、非干预性、前瞻性队列研究的亚分析。确定了133例接受抗逆转录病毒一线治疗的患者。通过逻辑回归分析，对初治患者治疗策略的决定因素进行了分析。

结果

与接受基于NNRTI的初始治疗方案的患者相比，接受PI/r治疗的患者年龄稍小，受教育程度较低处于HIV疾病晚期且合并症更多。回归分析显示，处于HIV疾病晚期（CDC-C）与基于PI/r的治疗决策显著相关。

结论

我们的分析是德国第一项研究与基于NNRTI或PI/r的初始治疗决策相关的社会人口统计学和疾病特异性参数的研究。结果证实，PI/r策略的治疗决策与疾病严重程度相关。